Ecolab 10-Qquarter ended 2026-09-30

Executive Summary

Ecolab sells water-treatment, cleaning, hygiene and pest-control products, equipment and services to industrial, hospitality, food-service and life-sciences customers. It is expanding into data-center cooling and microelectronics water treatment through CoolIT Systems and Ovivo Electronics, alongside growth in its established businesses. This quarter showed strong demand in High-Tech and Life Sciences, but acquisition financing, integration costs and higher taxes kept operating growth from reaching net earnings. The opportunity is a larger position in technology infrastructure; investors must weigh that against increased leverage and the need to turn acquisitions into cash-generating growth.

What's Happening in the Business

The acquisition of CoolIT Systems on 7/2/2026 materially expanded Ecolab’s data-center cooling business. Ecolab paid $4.63B net of acquired cash, following its December 2025 acquisition of Ovivo Electronics for $1.62B. Both sit within Global Water, linking Ecolab’s water-management capabilities to growing cooling and purification needs in technology infrastructure.

That expansion accompanies growth in existing operations. High-Tech organic sales rose 63%, driven by microelectronics and data-center wins. Management also reported growth across Water’s other businesses, suggesting technology demand is accelerating a broader business rather than masking contraction elsewhere.

Ecolab is using pricing and productivity to absorb higher energy, raw-material and logistics costs associated with geopolitical conflict and supply disruptions. An energy surcharge began in Q2. Management expects pricing, volume growth and savings to offset these pressures; this remains an execution requirement, not a guaranteed outcome.

The One Ecolab restructuring program targets $325M of annualized savings by 2027, with cumulative savings reaching $217M. Its importance has increased as acquisitions add financing and integration expenses.

Key Financial Highlights

Q3 and 9M ended 9/30/2026; changes are Y/Y.

Segment results below use reported currency; comparisons reflect the revised segment structure.

• Organic growth: Q3 sales rose 7%, comprising 5% pricing and 2% volume; acquisitions and divestitures added 6 percentage points to fixed-currency growth. For 9M, organic growth was 5%, including 1% volume growth.
• Segment drivers: Water organic growth was 9%. Life Sciences grew organically 17%, led by bioprocessing, pharmaceuticals, personal care and purification; its fixed-currency operating margin reached 23.3% from 18.3%. Institutional & Specialty organic growth was 3%, and Pest Elimination’s was 8%.
• Costs outside segments: Corporate operating expense increased to $162M from $74.8M, including acquisition-related intangible amortization and special charges. Company-wide Q3 special charges reached $82.9M vs $26.5M; acquisition and integration costs accounted for $42.2M.
• Financing: Total debt carrying amount, including current maturities, reached $13.2B, up 62% since year-end. Q3 net interest expense increased to $125M from $55.3M. Management’s net-debt-to-trailing-EBITDA ratio rose to 3.1 times from 2.0 times.
• Cash generation: 9M OCF was $1.94B, +4.1%, against net income of $1.52B. Noncash expenses supported the difference, while receivables, inventory and $200M of one-time acquired-employee incentive payments consumed cash. Capital expenditure rose 26% to $902M, leaving calculated FCF of $1.04B, down 9.5%.
• Capital returns: Repurchases were $672M vs $375M, and dividends were $629M vs $564M. Shares outstanding fell 0.5% since year-end; combined distributions exceeded FCF.

Risk Assessment

• Acquisition execution and valuation: Preliminary CoolIT accounting includes $3.25B of goodwill, while consolidated tangible common equity is negative $7.36B; weaker acquired-business performance could trigger impairments.
• Financing flexibility: Acquisition debt raises recurring interest costs, while $1.28B falls due within a year against $722M of cash; the unused $2.0B revolving facility provides liquidity.
• Cost recovery: Energy and supply-chain pressures could outrun Ecolab’s surcharge and pricing actions, squeezing margins if customers resist further increases.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• Technology expansion: High-Tech’s rapid organic growth and the CoolIT integration should produce sustained Water growth; slowing customer wins or integration charges without corresponding growth would weaken the thesis.
• Life Sciences: Strong organic growth and margin expansion need to persist across bioprocessing and pharmaceutical customers; slowing sales or margin reversal would challenge its growth contribution.
• Debt reduction: Leverage is elevated and capital returns exceed FCF. Later filings should show cash generation reducing debt rather than continued reliance on financing.
• One Ecolab savings: Management’s 2027 target requires further savings. Success means lower overhead supports margins without weakening sales; repeated charges without improvement would signal poor execution.